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Abstract
The scale-up of antiretroviral therapy (ART) in South Africa substantially reduced AIDS-
related deaths and new HIV infections. However, its success is threatened by the emer-
gence of resistance to non-nucleoside reverse-transcriptase inhibitors (NNRTI). The MAR-
ISA (Modelling Antiretroviral drug Resistance In South Africa) model presented here aims at
investigating the time trends and factors driving NNRTI resistance in South Africa. MARISA
is a compartmental model that includes the key aspects of the local HIV epidemic: contin-
uum of care, disease progression, and gender. The dynamics of NNRTI resistance emer-
gence and transmission are then added to this framework. Model parameters are informed
using data from HIV cohorts participating in the International epidemiology Databases to
Evaluate AIDS (IeDEA) and literature estimates, or fitted to UNAIDS estimates. Using this
novel approach of triangulating clinical and resistance data from various sources, MARISA
reproduces the time trends of HIV in South Africa in 2005–2016, with a decrease in new
infections, undiagnosed individuals, and AIDS-related deaths. MARISA captures the
dynamics of the spread of NNRTI resistance: high levels of acquired drug resistance (ADR,
in 83% of first-line treatment failures in 2016), and increasing transmitted drug resistance
(TDR, in 8.1% of ART initiators in 2016). Simulation of counter-factual scenarios reflecting
alternative public health policies shows that increasing treatment coverage would have
resulted in fewer new infections and deaths, at the cost of higher TDR (11.6% in 2016 for
doubling the treatment rate). Conversely, improving switching to second-line treatment
would have led to lower TDR (6.5% in 2016 for doubling the switching rate) and fewer new
infections and deaths. Implementing drug resistance testing would have had little impact.
The rapid ART scale-up and inadequate switching to second-line treatment were the key
drivers of the spread of NNRTI resistance in South Africa. However, even though some
interventions could have substantially reduced the level of NNRTI resistance, no policy
including NNRTI-based first line regimens could have prevented this spread. Thus, by
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Author summary
Resistance to non-nucleoside reverse transcriptase inhibitors (NNRTI) threatens the
long-term success of antiretroviral therapy (ART) roll-out in South Africa. We developed
a compartmental model integrating the local HIV epidemiology with biological mecha-
nisms of drug resistance. A first dimension of the model accounts for the continuum of
care: infection, diagnosis, first-line treatment with suppression or failure, and second-line
treatment. Other dimensions include: disease progression (CD4 counts), gender, and
acquisition and transmission of NNRTI resistance. Whenever possible, we informed the
parameters using the data available from local cohorts. Other parameters were informed
using literature or UNAIDS estimates. The model captured the rise of NNRTI resistance
during the period. We assessed the impact of counter-factual scenarios reflecting alterna-
tive countrywide policies during the period 2005 to 2016, considering either increasing
ART coverage, improving management of treatment failure, broadening ART eligibility,
or implementing drug resistance testing before ART initiation. We identified key drivers
of the NNRTI resistance epidemic: large-scale ART roll-out and insufficient monitoring
of first-line treatment failure. The model also suggested that no policy including NNRTI-
based first line regimens could have prevented the spread of NNRTI resistance.
Introduction
Since ART has been introduced in Southern Africa in 2004, ART coverage has continuously
increased. In 2016, 55% of individuals living with HIV were receiving ART in the region, the
great majority being treated with a standard first-line regimen consisting of two nucleoside
reverse transcriptase inhibitors (NRTI) and one non-nucleoside reverse transcriptase inhibitor
(NNRTI) [1]. The scale-up of ART led to a substantial reduction in mortality but the emer-
gence of drug resistance could jeopardize its long-term success [2]. Of particular concern are
NNRTIs, as this class has a relatively low genetic barrier to resistance [3]. As documented by
the World Health Organization (WHO), the level of pretreatment NNRTI resistance has rap-
idly increased and reached the 10% threshold in the Southern Africa region in 2015 [4].
According to WHO, this threshold should trigger considerations on changing the first-line
regimen. By contrast, resistance to NRTIs, though relevant at the individual level, is only rarely
transmitted [4].
In South Africa, adult HIV deaths have decreased from 220,000 in 2006 to 99,000 in 2014
[2]. In 2016, an estimated 63% of HIV positive people were on ART in South Africa [1]. While
initially only people with CD4 counts lower than 200 cells/μL were eligible to start ART, South
Africa adopted the “Treat All” policy in 2017, which recommends ART for all HIV-positive
people regardless of their CD4 counts [5]. The goal is to reach 90% of diagnosed people on
ART in 2020, in line with the 90-90-90 targets of UNAIDS [6]. While the HIV epidemic in
South Africa has been well described and extensively modelled [2,7,8], relatively little work has
been done on drug resistance [9,10]. The rapid increase in ART coverage might fuel further
increase in drug resistance as more and more people become exposed to the drug, but the
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impact of the scaling up of ART on the development of NNRTI resistance is not well defined
at present. Another key question is whether a better management of treatment failure would
have mitigated NNRTI resistance.
While understanding the drivers of antiretroviral resistance is crucial for public health, rep-
resentative, longitudinal data on drug resistance are scarce, compared to the large amount of
cohort data available on the clinical and public health epidemiology of HIV. Moreover, quanti-
fying the spread of resistance is challenging because it involves both epidemiological (trans-
mission, cascade of care, disease progression) and evolutionary processes (emergence and
selection of resistance mutations) [11–13], with the parameters governing the latter typically
unknown [13].
We aimed to capture the dynamics of NNRTI resistance in South Africa during 2005–2016
and to quantify the impact that different policy changes would have had on the rise of drug
resistance. To this end we developed MARISA (Modelling Antiretroviral drug Resistance In
South Africa), a mathematical model integrating the specificities of HIV epidemiology in the
country with the evolutionary epidemiology of drug resistance. MARISA is a compartmental,
deterministic model whose structure reflects gender-specific dynamics of continuum of care
and disease progression, as well as acquisition and transmission of HIV NNRTI resistance. We
calibrated the model using data from the International epidemiology Databases to Evaluate
AIDS in Southern Africa (IeDEA-SA, www.iedea-sa.org, [14]), literature estimates and HIV
key outcomes provided by UNAIDS [1]. The acquisition and transmission of NNRTI drug
resistance was integrated within the general dynamics of the HIV epidemic in the country and
parametrized with estimates derived from other cohorts. This allowed the estimation of the
yearly levels of acquired and transmitted drug resistance (ADR and TDR, respectively). We
then assessed the impact of counter-factual scenarios reflecting alternative countrywide public
health policies, including policies of increasing ART coverage, improving management of
treatment failure, broadening ART indications, or implementing drug resistance testing before
initiation.
Method
Model structure
MARISA is a mechanistic, compartmental model. The first dimension of the model accounts
for the whole continuum of care: infection of susceptible individuals, diagnosis, first-line treat-
ment including NNRTI with subsequent suppression or failure, and second-line treatment
including protease inhibitors (PI) with subsequent suppression or failure (8 classes). We then
consider three additional dimensions: disease progression as characterized by CD4+ T cell
counts (4 classes); NNRTI resistance status (2 classes); and gender (2 classes). This leads to a
total of 128 compartments. The first two dimensions describe the different care stages and
their interaction with HIV progression. The third dimension is key to capture the acquisition
of NNRTI resistance by individuals with first-line treatment failure (with rate σres), the trans-
mission of resistant strains of HIV to susceptible individuals, and the reversion of HIV resis-
tance mutations when no more drug pressure is exerted (with rate σrev). We assume that
individuals infected with the NNRTI resistant virus have higher failure and lower viral sup-
pression rates (hazard ratio α and α−1, respectively). As one mutation (e.g. the K103N muta-
tion) alone confers high-level resistance to NNRTI drugs [15], only one layer is used to
represent NNRTI resistance. The fourth dimension reflects differences observed between
women and men, with diagnosis and treatment rates being higher for women than for men
[16,17]. This dimension is also involved in modelling HIV transmission among adults (�15
years old).
Modelling the spread of antiretroviral resistance in South Africa
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Movement between compartments is determined by different rates, some of which change
over time to reflect modifications in treatment policies or in behavior. Adults living in South
Africa who are not infected are represented by the susceptible compartment (Susc), as shown
in Fig 1. The I compartments represent undiagnosed HIV-positive individuals. The force of
infection considers three transmission routes among adults: a man can either be infected by a
woman (“heterosexual” or HET transmission) or, less commonly, by a man (“men having sex
with men” or MSM transmission), while a woman can only be infected by a man. HET and
MSM populations are only implicitly modelled: we assume a density-dependent transmission
that accounts for different risk behaviors according to knowledge of HIV status (monthly
number of unprotected sexual contacts βu and βd for undiagnosed and diagnosed HIV-
infected individuals, respectively) and the expected proportion of HET and MSM among men.
Fig 1. Compartmental model. Three of the four dimensions are represented: 1) care stages (vertically), 2) disease progression (horizontally, stratified in 4 CD4 counts
strata), 3) NNRTI resistance (represented by the two overlapped layers). For sake of clarity, arrows representing treatment interruption are not displayed. Red arrows
represent acquisition of NNRTI resistance, while blue arrows represent reversion to wild-type HIV-strain.
https://doi.org/10.1371/journal.pcbi.1007083.g001
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Inflow of infected children reaching the age of 15 is also taken into account by using estimates
from the Thembisa model and published literature (See Section 1.5 in S1 File)[2,17–19].
Infected individuals become diagnosed at a rate γI!D(t) that is allowed to vary over time, by
CD4 count and by gender. Once diagnosed (compartment D), individuals will start treatment
at a rate gD!T1ðtÞ that also varies over time, reflecting the successive changes in ART guidelines.
This rate also depends on the CD4 count, as individuals with lower counts will initiate treat-
ment at higher rates (see Section 1.3 in S1 File).
First-line ART initiation is represented by the T1 compartment, which characterizes indi-
viduals who have been on ART for three months or less. After this period, they can either sup-
press viral replication (S1) or fail treatment (F1). These two compartments reflect the use of
viral load monitoring in South Africa to identify patients failing first-line treatment that should
switch to second-line regimen. We assume that virally suppressed individuals cannot transmit
the virus. When failing first-line treatment, individuals are switched to second-line treatment
(compartment T2) at rate gF1!T2 . Care and disease progression on second line treatment are
modelled identically to first-line therapy. Mortality at each stage differs according to disease
progression and care stage. In addition, the mortality rates for patients with CD4 counts below
200 cells/μl are time-dependent, due to the highly variable mortality risk in this class [20].
Overall, the model contains 137 different rates. The total population of each gender follows the
WHO estimates for South Africa, and initial conditions in each compartment reflect UNAIDS
estimates for 2005. Further details on the MARISA model are available in Sections 1 and 2 in
S1 File.
Parameter values and calibration procedure
We parameterized and calibrated the model in two successive steps. First, some parameters
were given fixed values using external sources. Literature estimates were used for parameters
related to NNRTI resistance (σres, σrev, and α), for transmission probabilities per sexual contact,
for the proportion of MSM and for the mortality risks (relatively to suppressed individuals
with more than 500 CD4/μL). Similarly, values were defined for the time-dependent diagnosis
rates (differentiating between testing asymptomatic individuals, symptomatic individuals and
pregnant women, and relatively to the treatment rate in 2005) and treatment rates (relatively
to the treatment rate for an eligible individual with less than 200 CD4/μL in 2005). We used
estimates from studies conducted in South Africa whenever available. For parameters related
to disease progression (movements between CD4 strata) and to the continuum of care after
starting first-line treatment (rates of suppression, treatment failure, switching to second line,
and treatment interruption), we used data from five IeDEA cohorts in South Africa (Aurum
Institute, Hlabisa, Khayelitsha, Kheth’Impilo and Tygerberg) that provided longitudinal infor-
mation for 54,016 HIV-infected adults [14]. The majority of them were female (62%). All
patients started a first-line regimen and 3905 (7.2%) received a second-line regimen. Viral load
measurements were used to identify the occurrence of suppression or treatment failure in
treated individuals (using a threshold of 1000 copies/mL). Because of low monitoring fre-
quency, the number of available measurements per patient was limited and some intermediate
steps in disease or care progression were missing. We thus adapted methods from survival
analysis in order to reconstruct patients’ care histories (see Section 3.1 in S1 File). See Table 1
for more details about parameters.
During the second phase, the 7 remaining unknown parameters were estimated by fitting
the model to estimates from the Thembisa model for the period 2005 to 2015: annual numbers
of new HIV infections, number of undiagnosed individuals, annual number of AIDS-related
deaths and ART coverage (Table 2 and Fig 2). The Thembisa model is a compartmental model
Modelling the spread of antiretroviral resistance in South Africa
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providing UNAIDS with estimates on the South African HIV epidemic. Inference relied upon
a maximum likelihood approach, assuming Poisson-distributed errors. We thus obtained
point estimates for the monthly numbers of unprotected sexual contacts βu and βd, for the base
diagnosis rate in 2005 and its increase between 2005 and 2016, for the treatment rate in 2005,
for a scale parameter modelling the decrease in the proportion of individuals with CD4<50
cells/μL (only used for mortality estimates), and for the mortality rate of suppressed individu-
als with more than 500 CD4/μL (see Table 1). Further details are available in the Section 3 in
S1 File.
Simulations and counterfactual scenarios
The model was simulated from 2005 to 2016 using the specified parameter values and a
monthly time step. Several outcomes were computed from the output, including the propor-
tions of NNRTI ADR (proportion of individuals in F1 compartments with NNRTI resistance,
Table 1. Parameters used in the model. IeDEA cohort data were used to estimate clinical progression rates.
Parameters that could not be estimated with these data were collected from literature. Finally, time-varying parameters
were estimated by fitting the MARISA model to estimates from Thembisa model.
Parameters Definition Reference
Parameters obtained from literature (see Table 4 in S1 File)
Resistance parameters
σres Rate of acquiring NNRTI resistance when failing 1st-line
treatment
[21]
σrev Reversion rate when no more NNRTI-drug pressure [22]
α Positive impact of NNRTI resistance on treatment failure [23]
HIV-transmission parameters
Probabilities of HIV infection across gender [24]
MSM prevalence [25]
Mortality parameters
Relative mortality risks across CD4 strata and care treatment
status
[20,26]
Diagnosis and treatment rates
γI!D(t)
gD!T1 ðtÞ
Diagnosis rates according to gender and CD4 strata
Treatment rates according to CD4 strata
[17]
[17]
Parameters estimated of IeDEA cohort data by survival analysis (see Tables 2 and 3 in S1 File)
Parameters related to disease progression [14]
Transition rates between CD4 strata
Parameters related to continuum of care
gT1!S1 ; gF1!S1 ; gT2!S2 ; gF2!S2 Suppression rates for first- and second-line treatment
gT1!F1 ; gS1!F1 ; gT2!F2 ; gS2!F2 Failure rates for first- and second-line treatment
gF1!T2 Switching rate from first- to second-line treatment
gT1!D; gS1!D; gF1!D; gT2!D; gS2!D; gF2!D Treatment interruption rates
Parameters estimated by fitting MARISA to Thembisa model data (see Table 5 in S1 File)
βu, βd monthly numbers of unprotected sexual contacts for
undiagnosed and diagnosed people respectively
[1,17]
γI!D(2005),
γI!D(2016)/γI!D(2005)
base diagnosis rate in 2005 and its increase between 2005 and
2016
gD!T1 ð2005Þ treatment rate in 2005
q scale parameter modelling the decrease in the proportion of
individuals with CD4<50 cells/μL
mi¼1S1=s2 mortality rate of suppressed individuals with >500 CD4/μL.
https://doi.org/10.1371/journal.pcbi.1007083.t001
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see Eq 15 in S1 File) and of NNRTI TDR (proportion of individuals coming from I to D com-
partments with NNRTI resistance). When not specified otherwise, NNRTI TDR is measured
in newly diagnosed patients (D) (see Eq 16 in S1 File). Alternatively, we determine the propor-
tion of NNRTI resistance in newly infected patients, newly diagnosed patients or in ART initi-
ators. In this latter case, as it comprises drug-experienced people, we used the term pre-
treatment drug resistance (PDR), rather than TDR.
Four counterfactual scenarios were examined with the model. The first counterfactual sce-
nario assessed the impact of treatment initiation (gD!T1 ) increased by factors 2, 3 or 5. The sec-
ond counterfactual scenario investigated the impact of an earlier switch to second-line
regimen (gF1!T2 ) when failing the first-line regimen, by factors 2, 5 or 10. The third and fourth
scenario examined the impact of different testing and treatment policies. In the third scenario,
the “Treat All” policy, i.e. initiating first-line treatment of diagnosed individuals regardless of
CD4 counts, was implemented at a hypothetical earlier point in time (moved forward by 1.5, 3
or 6 years). The fourth scenario implemented drug resistance testing and immediate second-
line treatment of individuals harboring a resistant strain at baseline.
Sensitivity analysis
We performed a multivariate sensitivity analysis in order to quantify the impact of uncertainty
on the values of 1) four parameters related to NNRTI resistance (σres, σrev, α and the rates of
treatment interruption) and 2) three parameters related to HIV transmission (percentage of
MSM, probability of male-to-male infection per sexual contact, and ratio between HIV preva-
lence in MSM and HET). Multivariate uncertainty within specified ranges was introduced
using Latin hypercube sampling [29]. Each model estimate is reported with a 100% sensitivity
range. Further details are available in Section 4.2 in S1 File.
Results
Model outcomes
The model reproduces the main time trends of the HIV epidemic in South Africa 2005–2016
(Fig 2A–2D). There is a clear increase in ART coverage since 2005, attaining 48% of infected
individuals in 2015, and a significant drop in the number of undiagnosed individuals, as a
result of the increasing number of HIV tests performed annually. In 2015, the model estimated
Table 2. Outcomes and data sources used to calibrate the model and to compare the resistance related outcomes of the model. The six outcomes are displayed in Fig
2. See Section 3.2 in S1 File for more details.
Outcome Definition Source Reference
Data used during the fitting procedure
New infections Number of newly HIV-infected adults per year Thembisa model [17]
Undiagnosed
people
Number of undiagnosed HIV-infected adults Thembisa model [17]
AIDS-related
deaths
Number of AIDS-related deaths per year (for adults) Thembisa model [17]
Treatment
coverage
Percentage of HIV-infected adults that are treated UNAIDS data [1]
Resistance estimates from cross-sectional studies
Level of NNRTI
ADR
Percentage of people failing first-line treatment that
are resistant to NNRTI
2 cross-sectional studies done in 2010 and 2014 in South Africa [21,27]
Level of NNRTI
TDR
Percentage of treatment-naïve people that are
resistant to NNRTI
Data from a systematic review on the prevalence of PDR in South Africa, among
other low and middle income countries.
[28]
https://doi.org/10.1371/journal.pcbi.1007083.t002
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that 0.79 million of the 6.9 million infected individuals (11.4%) were not yet diagnosed. The
number of yearly newly-infected individuals decreased from over 400,000 individuals in 2006
to about 300,000 in 2016. The decrease in risk behavior due to testing among HIV-positive
individuals is estimated at 46% (βd/βu = 0.54), in line with a behavioral study conducted in
South Africa in 2013 [30]. Finally, HIV-related deaths dropped from over 200,000 in 2006 to
109,000 in 2016.
The MARISA model also captures the dynamics of NNRTI ADR and TDR, showing very
high levels of ADR (Fig 2E) and increasing levels of TDR (Fig 2F) in South Africa after 2004.
Fig 2. Best fit of the model. The plots a, b, c and d correspond to the four outcomes used during the fitting procedure: A) the number of newly infected per year, B) the
total number of undiagnosed individuals at each year, C) the number of AIDS-related deaths per year and D) the percentage of infected individuals that are on ART.
NNRTI ADR and TDR levels are displayed in E and, F and G respectively, and are not used to fit the model. Lines correspond to model output and circles to Thembisa
estimates (in red) or to results from cross-sectional studies (in blue, see Table 6 in S1 File). Grey shades correspond to 100% sensitivity ranges. See Table 2 for more details.
https://doi.org/10.1371/journal.pcbi.1007083.g002
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The model estimates that 73% of the individuals failing the first-line regimen had ADR to
NNRTI in 2008, with a slight yet steady increase in the following years, surpassing 83% in
2016. Moreover, the model estimated that 13.8% of these individuals were already resistant at
the time of failure. NNRTI TDR among newly diagnosed individuals increased from 0.9% to
8.1% during the period. Interestingly, the model indicates substantial variation in TDR levels
over the four CD4 strata, ranging from 2.9% for newly diagnosed individuals with less than
200 CD4/μL to 10.0% for those with more than 500 CD4/μL in 2016. For newly infected indi-
viduals, the NNRTI TDR level reaches 15.0% in 2016. We also observe a high PDR prevalence
among individuals initiating first-line ART (6.5% in 2016). Finally, the model estimated that
16.9% of ADR cases in 2016 were related to TDR (see Eq 17, in S1 File).
Counterfactual scenarios
In the first scenario, increasing the treatment rate by a factor 2, 3 or 5 during the whole period
would have led to a substantial reduction of the number of annual deaths, but would have had
little effect on the number of newly-infected or the number of undiagnosed individuals (Fig 3).
The decrease in new infections due to increased treatment rates is modest for two reasons: 1)
the low proportion of HIV-infected individuals who are ART eligible (only 28% of HIV-
infected individuals are diagnosed in 2005) and 2) the decrease in the number of deaths of
infectious individuals when increasing ART coverage (67,000 deaths of infectious individuals
prevented per year in 2005–2012 under the 5-fold increase scenario). As expected, increasing
treatment rates would not have impacted NNRTI ADR levels. On the other hand, by increas-
ing the number of individuals at risk of acquiring NNRTI resistance, it would have led to a
considerable increase of NNRTI TDR levels, surpassing 15.0% in 2016 in the 5-fold increase
scenario.
In the second scenario, increasing the rate of switching to second-line treatment in case of
first-line treatment failure (i.e. dividing the time spent in treatment failure) by factors 2, 5 or
10 would not have influenced the four key HIV outcomes (Fig 4). However, the model predicts
a substantial decrease in the levels of both NNRTI ADR and TDR (to 51.5% and 3.1%, respec-
tively), for the 10-fold increase scenario compared to 83% and 8.1%, respectively, for the base-
line model in 2016.
Moving the “Treat-All” policy forward in time by 1.5, 3 or 6 years in the third scenario,
would have hardly reduced mortality, as it targets individuals with high CD4 counts. On the
other hand, removing infectious individuals with high CD4 counts, who are most likely to
achieve viral suppression, would have led to a decrease in the number of new infections
(256,000 for the 6-year-early implementation scenario instead of 302,000 in the baseline model
in 2016). Increasing ART coverage might, however, increase the spread of resistance as
NNRTI TDR increased to 10.3% in this scenario.
Finally, in the fourth scenario, drug resistance testing, by directly starting individuals with
NNRTI resistance on second-line regimens, would have slightly improved viral suppression
among resistant individuals (59.3% instead of 56.9% in the baseline model) and also reduced
the transmission of resistance (14.4% instead of 15% resistant among newly infected in 2016).
The relative impact of each counterfactual scenario on the number of new infections, AIDS-
related deaths and the numbers of both new NNRTI TDR and ADR cases in 2016, as well as
their relative percentages is shown in Table 3.
Sensitivity analysis
Sensitivity analyses showed that uncertainty in the values of four resistance-related parameters
(σres, σrev, α and the rates of treatment interruption) and of three parameters related to HIV
Modelling the spread of antiretroviral resistance in South Africa
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transmission (percentage of MSM, probability of male-to-male infection per sexual contact,
and ratio between HIV prevalence in MSM and HET) did not modify substantially the main
outcomes of the MARISA model (Fig 2).
Discussion
In this comprehensive modelling study, we show that the MARISA model captured the
dynamics of the HIV epidemic in South Africa over the years 2005–2016. More importantly, it
Fig 3. Counterfactual scenario that investigates the impact of increased treatment rate. Simulations of the MARISA model from 2005 to 2016 under the scenarios
where the treatment rate is increased by 2, 3 and 5, represented respectively by the blue, red and yellow curves. Simulations of the baseline model are represented in black.
The following HIV outcomes are displayed: A) the number of newly infected per year, B) the total number of undiagnosed individuals at each year, C) the number of
AIDS-related deaths per year and D) the percentage of infected individuals that are on ART, E) level NNRTI ADR and F) level of NNRTI TDR. Different colours
correspond to different rates of starting treatment, where the rates are expressed as multiple of the rate in the standard model. The coloured circles and vertical lines at the
right of each sub-figure correspond to the point estimates and 100% sensitivity ranges in 2016, respectively.
https://doi.org/10.1371/journal.pcbi.1007083.g003
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reproduced the emergence of NNRTI resistance, following the roll-out of ART in 2004. The
four counterfactual scenarios provided insights into the drivers of NNRTI resistance. They
highlighted the close association between the magnitude of ART roll-out and the extent of
NNRTI drug resistance. The results also suggest that a better management of first-line treat-
ment failure, improving identification of treatment failure and switching to second-line treat-
ment, might have reduced AIDS-related mortality and new HIV infections, while offering a
Fig 4. Counterfactual scenario that investigates the impact of increased switching rate to second line regimen. Simulations of the MARISA model from 2005 to 2016
under the scenarios where the switching rate to second-line regimen gF1!T2 is increased by factor 2, 5 and 10, represented respectively by the blue, red and yellow curves. In
the baseline simulations represented by the black curves, a switching rate gF1!T2 of 1/2.9 years
−1 is assumed for individuals with CD4<200 copies/μl. The following HIV
outcomes are displayed: A) the number of newly infected per year, B) the total number of undiagnosed individuals at each year, C) the number of AIDS-related deaths per
year and D) the percentage of infected individuals that are on ART, E) level NNRTI ADR and F) level of NNRTI TDR. Different colours correspond to different rates of
starting treatment, where the rates are expressed as multiple of the rate in the standard model. The coloured circles and vertical lines at the right of each sub-figure
correspond to the point estimates and 100% sensitivity ranges in 2016, respectively.
https://doi.org/10.1371/journal.pcbi.1007083.g004
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better control of NNRTI resistance. However, our results also show that while some policies
result in substantial reductions in NNRTI TDR, no measure could have stopped its increase.
Even with optimal monitoring and management, NNRTI resistance would have rapidly spread
in South Africa, suggesting that NNRTI resistance is inevitable if NNRTI-based regimens are
used for first-line therapy.
The MARISA model fit was good regarding all four key outcomes of the HIV epidemic in
South Africa produced by Thembisa/UNAIDS for the period of study: new infections, number
of undiagnosed individuals, AIDS-related deaths and ART coverage [1,17]. The estimates
related to the “90-90-90” target provided by our model are also in line with those from
UNAIDS. The proportion of HIV-infected individuals knowing their HIV status was esti-
mated at 88% and 86% in 2015 by our model and UNAIDS, respectively. The second “90” was
slightly underestimated by the MARISA model: the proportion of individuals with diagnosed
HIV infection receiving ART was estimated at 52% in 2015, compared to estimates of 56% and
60% from Thembisa and UNAIDS, respectively. Finally, the proportion of individuals receiv-
ing ART achieving viral suppression was estimated at 79%, compared to 78% by UNAIDS [1].
NNRTI ADR and TDR levels estimated by the MARISA model were comparable, though
slightly lower, to estimates from six cross-sectional studies conducted during this period
[21,27,31–33]. Of note, these observational data were not used for model calibration and the
Table 3. Impact of counterfactual scenarios on six outcomes: Yearly death, new infections, TDR level, ADR level, number of TDR cases, number of ADR cases, all
in 2016. For each of the 6 outcomes and each of the 10 counterfactual scenarios, the absolute difference between the given scenario and baseline model, as well as the
100% sensitivity range (100% SR) are calculated.
Outcome Scenario 1:
Increasing treatment rate
Scenario 2:
Increasing switching rate
Scenario 3:
Earlier Treat-All
Scenario 4:
DR testing
2�γ 3�γ 5�γ 2�γ 5�γ 10�γ 1.5 years 3 years 5 years
Death
Mean (per
1000)
-38.5 -52.0 -61.4 -5.0 -10.0 -12.2 -0.0 -1.3 -8.1 -1.1
100% SR (-41.2,-
38.1)
(-56.4,-
51.6)
(-67.3,-
60.9)
(-6.7,-3.6) (-13.6,-7.6) (-16.7,-9.5) (-0.0,0.0) (-0.0,0.0) (-8.5,-7.1) (-2.9,-0.5)
New inf.
Mean (per
1000)
-30.5 -47.0 -65.0 -8.8 -18.0 -22.4 -5.2 -20.5 -45.8 -2.1
100% SR (-34.3,-
27.0)
(-53.2,-
41.9)
(-73.9,-
58.6)
(-11.3,-5.5) (-22.5,-12.1) (-27.6,-15.7) (-5.9,-5.1) (-22.7,-
19.8)
(-49.7,-
43.4)
(-4.7,-0.9)
TDR level
Mean (in %) 3.3% 5.1% 6.8% -1.7% -3.8% -5.1% 0.1% 0.6% 2.1% -0.3%
100% SR (1.8%,4.2%) (2.7%,6.4%) (3.6%,8.8%) (-2.0%,-
0.8%)
(-4.5%,-2.0%) (-6.1%,-2.7%) (0.1%,0.1%) (0.4%,0.8%) (1.1%,2.6%) (-0.7%,-
0.1%)
ADR level
Mean (in %) 1.5% 2.2% 2.9% -6.4% -19.4% -31.5% -0.7% 0.7% 2.2% -1.4%
100% SR (1.0%,2.9%) (1.4%,4.3%) (1.8%,5.7%) (-8.8%,-
4.4%)
(-24.3%,-
14.3%)
(-36.5%,-
25.0%)
(-1.1%,-
0.4%)
(0.6%,0.9%) (1.6%,3.1%) (-3.9%,-
0.8%)
TDR cases
Mean (per
1000)
12.3 17.3 21.2 -9.6 -20.9 -27.7 0.6 3.2 6.0 -2.0
100% SR (8.6,16.9) (11.8,24.4) (14.2,30.9) (-12.0,-6.2) (-25.4,-14.4) (-33.3,-19.3) (0.3,0.9) (2.2,4.3) (4.3,8.3) (-4.5,-0.8)
ADR cases
Mean (per
1000)
31.8 40.5 47.3 -14.3 -44.7 -74.8 19.4 27.1 7.7 -0.1
100% SR (29.3,39.0) (37.7,50.2) (43.9,58.3) (-19.0,-10.3) (-54.0,-34.5) (-83.1,-62.0) (14.8,23.0) (25.1,28.1) (6.1,11.4) (-0.3,-0.0)
https://doi.org/10.1371/journal.pcbi.1007083.t003
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resistance-specific processes of the MARISA model were partly informed using published esti-
mates from other settings (in particular the rate of reversion to a drug-susceptible strain [22]
and the positive association between drug resistance and treatment failure [23]), since no data
for South Africa were available. Beyond sampling variability in the estimates from the cross-
sectional studies, the discrepancy in ADR and TDR estimates between MARISA and the cross-
sectional studies could be explained by several factors: a higher proportion of individuals with
previous exposure to ART in the studied samples (e.g. through prevention of mother-to-child
transmission, not included in the MARISA model), selection bias in the cross-sectional studies
(e.g. regarding gender, age, socio-economic features or time since infection), publication bias
by which lower measurements of ADR and TDR are less likely to be published, or possibly a
misspecification of some parameters of the MARISA model due to geographical differences.
Note that TDR and ADR reflect different populations and processes. ADR is measured in
people failing therapy, while TDR is measured in newly diagnosed individuals. The term ADR
is somewhat imprecise since we measure it as the proportion of all drug resistant infections
among individuals failing treatment and some of these individuals acquired the resistance
already by infection. It reflects, however, the terminology used in resource limited settings,
where baseline resistance tests are not routinely performed. Our simulations showed that the
vast majority of these ADR cases were indeed acquired after treatment failure: in 2016, only
16.9% of ADR cases resulted from treatment failing in individuals already infected with a resis-
tant virus, while the remaining resulted from the selection of resistance mutations in individu-
als failing on therapy with an initially sensitive virus (see Eq 17 in S1 File). This patterns also
explains the relatively weak increase over time (from a high initial level) that is observed for
ADR (Fig 2E).
Interestingly, MARISA revealed heterogeneity in NNRTI TDR levels across CD4 strata,
with higher levels of NNRTI TDR associated with higher CD4 counts. This can be explained
by the fact that individuals with high CD4 counts are more likely to have been recently
infected, and thus exposed to a higher risk of NNRTI TDR as the prevalence of NNRTI-resis-
tance increases with time. Other studies have indeed observed a higher NNRTI TDR level
among acutely than chronically HIV-infected patients [34]. Given that untreated patients with
low CD4 counts might have been infected for a longer time, another explanation could be the
increased probability of reversion from a drug-resistant to a wild-type strain in these patients.
The counterfactual scenarios identified two main drivers of the emergence and spread of
NNRTI-resistance: the magnitude of the ART roll-out and low frequency of monitoring of
first-line treatment failure. The first scenario underlined the inherent risks of resistance emer-
gence induced by a rapid and generalized ART scale-up. This observation is supported by find-
ings of Hamers et al. [35] that the level of NNRTI TDR is associated with time since ART roll
out in sub-Saharan Africa. According to the first scenario, policies focused on increasing ART
coverage would have allowed a better control of the HIV epidemic, reducing both mortality
and new infections. However, such policies would have likely resulted in even higher levels of
NNRTI TDR during 2005–2016, leaving doubt about the long-term sustainability of this
approach. As seen in the second counterfactual scenario, an earlier treatment switch for indi-
viduals failing NNRTI-based treatment would not have prevented resistance from emerging.
In this context, the high NNRTI-mutation rate (after on average 6 months in the presence of
treatment failure) makes the emergence of NNRTI resistance almost inevitable. For instance,
we observe an emergence of TDR (3.3% in 2016) and a substantial level of ADR (50% in 2016),
even when assuming that from 2005 an optimal management of treatment failure complying
with the South African Department of Health 2016 guidelines [36] was in place. The guidelines
recommend a VL measure every six months and an immediate switch to second-line ART
after failure of two months of adherence counselling (corresponding to an average time before
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switching of 1=gF1!T2 = 5 months). Still, policies focused on improving first-line treatment fail-
ure identification and early switching to second-line treatment would have likely led to better
control of both the HIV epidemic (with fewer AIDS-related deaths and new infections) and
the extent of NNRTI resistance in South Africa. An earlier implementation of the “Treat-All”
policy in the third scenario would have modestly decreased mortality, as it extends ART to
individuals with high CD4 counts. However, the simulations emphasized the risk of increased
levels of NNRTI TDR following implementation of this policy, in a similar way to policies sim-
ply increasing ART coverage. Finally, the fourth scenario showed the limited impact on HIV
outcomes of implementing drug resistance testing at baseline. Immediate PI-based treatment
in patients with TDR only slightly diminished NNRTI TDR prevalence. This small effect may
be explained by the limited number of patients affected by the policy (i.e. newly-infected indi-
viduals carrying a resistant strain and initiating ART), whose contribution to the transmission
of resistance was relatively small (TDR accounts for only 16.9% of ADR cases). We acknowl-
edge that assuming the same failure rates in the counterfactual scenario for patients on a PI-
based first-line regimen as for patients on a PI-based second-line regimen may lead to under
estimation of the effect of baseline resistance monitoring, because rates of failure in patients
on first-line PI-based regimen are probably lower.
The model has several limitations. First, as the estimates from the Thembisa model were
used to fit MARISA, findings produced by MARISA partly rely on the accuracy of Thembisa
model. Second, it does not take into account NRTI mutations, which could also affect the suc-
cess of first-line treatment. However, as transmission of NRTI mutations remains at a low
level, their impact on the overall effectiveness of first-line regimens is limited [4]. Third, adher-
ence is not modelled explicitly in the model, as it is not systematically assessed in the IeDEA
cohorts. Nevertheless, adherence is implicitly included in MARISA, as estimates of suppres-
sion and failure rates rely on a large cohort of individuals with different levels of adherence.
Moreover, modelling of HIV transmission was based on simplified assumptions: the model
only distinguished male from female transmission and attributed two different transmission
rates according to awareness of HIV-status. The probability of HIV-infection per sexual act
was assumed to be identical for all unsuppressed individuals. The heterogeneity in sexual
behavior within genders was only approximated, and MARISA does not account for interac-
tions between resistance status and sexual behavior. However, in view of the good fit to the
number of new infections, there is no need for introducing a more complex representation of
HIV transmission dynamics. Finally, the model does not simulate prevention of mother-to-
child transmission, which could be an important source of NNRTI resistance. Overall, there is
a trade-off between these potential additional layers of complexity and the limited knowledge
about specific mechanisms. We argue that the ability of the MARISA model to capture the
dynamics of NNRTI resistance with parameters fixed to known values from external data sup-
ports the validity of these simplifications. As it stands, the model does not make any unverifi-
able assumptions, and the sensitivity analyses showed that conclusions were robust, despite
uncertainty in the main parameters related to resistance and transmission. Furthermore, the
relatively simple representation of NNRTI resistance emergence and transmission makes the
model easily interpretable.
MARISA can be adapted to address other questions on HIV drug resistance by adding fur-
ther layers of complexity. The imminent roll-out of Dolutegravir (DTG) has been presented as
a response to the NNRTI resistance epidemic [5]. In South Africa, DTG in combination with
two NRTI-class drugs will progressively replace NNRTI as the first-line regimen for men, but
there is uncertainty as to whether it should be recommended for women of reproductive age
due to safety issues [37]. DTG will also be prescribed to patients failing NNRTI-based
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regimens. As NRTI resistance mutations might already have occurred in these patients, this
could affect the future success of the DTG-based regimen [38,39]. From this basis, MARISA
can be extended in order to evaluate the potential impact of introducing DTG-based regimens,
either for men and women or for men only. While the overall structure of the model in terms
of care and disease progression will stay unchanged, the resistance dimension can be expanded
by adding key NRTI-resistance mutations (e.g. K65R and M184V). We could also stratify the
model by age group in order to represent the difference in drug prescription (NNRTI or DTG)
in women according to age. MARISA could thus be used to predict the spread of NRTI- and
NNRTI-resistance mutations according to the different strategies of DTG roll-out and their
impact on the overall success of HIV-epidemic.
To conclude, we propose MARISA, a mechanistic model aimed at providing insight into
the NNRTI resistance epidemic in South Africa in 2005–2016. Integrating information from
several sources, including local cohorts of HIV-infected individuals, the model captured the
essence of NNRTI resistance emergence in South Africa. Counter-factual scenarios identified
key drivers of the NNRTI resistance epidemic at the policy level: a rapid, large-scale ART roll-
out and an insufficient monitoring of first-line treatment failure. The model also showed that
the rapid rate of acquisition and slow rate of reversion of NNRTI drug resistance mutations
make it difficult to prevent their spread if NNRTI-based treatments are used as a first-line regi-
men, and it indicated the limited effect of drug resistance testing. Understanding future chal-
lenges in HIV drug resistance such as the introduction of DTG, its effect on the epidemic, the
possibility of DTG resistance, and the impact of NRTI mutations on DTG based regimens will
require the modelling of a more complex and uncertain mutational landscape. MARISA, with
its backbone of a simple yet adequate epidemiological model will provide a suitable foundation
to address this challenge.
Supporting information
S1 File. Detailed description of the MARISA model. Detailed description of the MARISA
model and the computational methods used to calibrate and then run it.
(PDF)
Author Contributions
Conceptualization: Anthony Hauser, Matthias Egger, Roger D. Kouyos.
Formal analysis: Anthony Hauser, Katharina Kusejko.
Methodology: Anthony Hauser, Katharina Kusejko, Leigh F. Johnson, Gilles Wandeler, Julien
Riou, Fardo Goldstein, Matthias Egger, Roger D. Kouyos.
Supervision: Matthias Egger, Roger D. Kouyos.
Writing – original draft: Anthony Hauser, Katharina Kusejko, Matthias Egger, Roger D.
Kouyos.
Writing – review & editing: Anthony Hauser, Katharina Kusejko, Leigh F. Johnson, Gilles
Wandeler, Julien Riou, Fardo Goldstein, Matthias Egger, Roger D. Kouyos.
References
1. UNAIDS. South Africa | UNAIDS data [Internet]. [cited 26 Jun 2018]. Available: http://www.unaids.org/
en/regionscountries/countries/southafrica
2. Johnson LF, May MT, Dorrington RE, Cornell M, Boulle A, Egger M, et al. Estimating the impact of anti-
retroviral treatment on adult mortality trends in South Africa: A mathematical modelling study. Suthar
Modelling the spread of antiretroviral resistance in South Africa
PLOS Computational Biology | https://doi.org/10.1371/journal.pcbi.1007083 June 24, 2019 15 / 17
AB, editor. PLOS Med. Public Library of Science; 2017; 14: e1002468. https://doi.org/10.1371/journal.
pmed.1002468 PMID: 29232366
3. Tang MW, Shafer RW. HIV-1 Antiretroviral Resistance. Drugs. 2012; 72: e1–e25. https://doi.org/10.
2165/11633630-000000000-00000 PMID: 22686620
4. WHO. WHO | HIV drug resistance report 2017 [Internet]. WHO. World Health Organization; 2017. Avail-
able: http://www.who.int/hiv/pub/drugresistance/hivdr-report-2017/en/
5. Meintjes G, Moorhouse MA, Carmona S, Davies N, Dlamini S, Van Vuuren C, et al. Adult antiretroviral
therapy guidelines 2017. South Afr J HIV Med. 2017; 18. Available: http://www.sajhivmed.org.za
6. Joint United Nations Programme on HIV/AIDS (UNAIDS). 90-90-90. An ambitious treatment target to
help end the AIDS epidemic [Internet]. Geneva; 2014. Available: http://www.unaids.org/sites/default/
files/media_asset/90-90-90_en_0.pdf
7. Eaton JW, Johnson LF, Salomon JA, Ba¨rnighausen T, Bendavid E, Bershteyn A, et al. HIV Treatment
as Prevention: Systematic Comparison of Mathematical Models of the Potential Impact of Antiretroviral
Therapy on HIV Incidence in South Africa. Bartlett J, editor. PLoS Med. 2012; 9: e1001245. https://doi.
org/10.1371/journal.pmed.1001245 PMID: 22802730
8. Estill J, Egger M, Blaser N, Vizcaya LS, Garone D, Wood R, et al. Cost-effectiveness of point-of-care
viral load monitoring of antiretroviral therapy in resource-limited settings: mathematical modelling study.
AIDS. NIH Public Access; 2013; 27: 1483–92. https://doi.org/10.1097/QAD.0b013e328360a4e5 PMID:
23462219
9. Cambiano V, Bertagnolio S, Jordan MR, Pillay D, Perrie¨ns JH, Venter F, et al. Predicted levels of HIV drug
resistance. AIDS. 2014; 28: S15–S23. https://doi.org/10.1097/QAD.0000000000000082 PMID: 24468943
10. Phillips AN, Stover J, Cambiano V, Nakagawa F, Jordan MR, Pillay D, et al. Impact of HIV Drug Resis-
tance on HIV/AIDS-Associated Mortality, New Infections, and Antiretroviral Therapy Program Costs in
Sub–Saharan Africa. J Infect Dis. Oxford University Press; 2017; 215: 1362–1365. https://doi.org/10.
1093/infdis/jix089 PMID: 28329236
11. Grenfell BT, Pybus OG, Gog JR, Wood JLN, Daly JM, Mumford JA, et al. Unifying the Epidemiological
and Evolutionary Dynamics of Pathogens. Science (80-). 2004; 303: 327–332. https://doi.org/10.1126/
science.1090727 PMID: 14726583
12. Kouyos RD, Metcalf CJE, Birger R, Klein EY, Abel zur Wiesch P, Ankomah P, et al. The path of least
resistance: aggressive or moderate treatment? Proc R Soc B Biol Sci. 2014; 281: 20140566–
20140566. https://doi.org/10.1098/rspb.2014.0566 PMID: 25253451
13. Metcalf CJE, Birger RB, Funk S, Kouyos RD, Lloyd-Smith JO, Jansen VAA. Five challenges in evolution
and infectious diseases. Epidemics. Elsevier; 2015; 10: 40–44. https://doi.org/10.1016/j.epidem.2014.
12.003 PMID: 25843381
14. Egger M, Ekouevi DK, Williams C, Lyamuya RE, Mukumbi H, Braitstein P, et al. Cohort Profile: The
international epidemiological databases to evaluate AIDS (IeDEA) in sub-Saharan Africa. Int J Epide-
miol. 2012; 41: 1256–1264. https://doi.org/10.1093/ije/dyr080 PMID: 21593078
15. Stanford University. NNRTI Resistance Notes—HIV Drug Resistance Database [Internet]. [cited 7 Aug
2018]. Available: https://hivdb.stanford.edu/dr-summary/resistance-notes/NNRTI/#k103n.s.h.t.r.q.e
16. Johnson LF, Rehle TM, Jooste S, Bekker L-G. Rates of HIV testing and diagnosis in South Africa.
AIDS. 2015; 29: 1401–1409. https://doi.org/10.1097/QAD.0000000000000721 PMID: 26091299
17. Johnson LF, Dorrington RE. Thembisa version 4.1: A model for evaluating the impact of HIV/AIDS in
South Africa [Internet]. 2018. Available: https://www.thembisa.org/publications
18. Fairlie L, Bernheimer J, Sipambo N, Fick C, Kuhn L. Lamivudine monotherapy in children and adoles-
cents: The devil is in the detail. South African Med J. 2017; 107: 1055. https://doi.org/10.7196/SAMJ.
2017.v107i12.12776 PMID: 29262955
19. Muri L, Gamell A, Ntamatungiro AJ, Glass TR, Luwanda LB, Battegay M, et al. Development of HIV
drug resistance and therapeutic failure in children and adolescents in rural Tanzania: an emerging pub-
lic health concern. 2016; https://doi.org/10.1097/QAD.0000000000001273 PMID: 27677163
20. Maduna PH, Dolan M, Kondlo L, Mabuza H, Dlamini JN, Polis M, et al. Morbidity and Mortality Accord-
ing to Latest CD4+ Cell Count among HIV Positive Individuals in South Africa Who Enrolled in Project
Phidisa. Andrei G, editor. PLoS One. 2015; 10: e0121843. https://doi.org/10.1371/journal.pone.
0121843 PMID: 25856495
21. Orrell C, Walensky RP, Losina E, Pitt J, Freedberg KA, Wood R. HIV type-1 clade C resistance geno-
types in treatment-naive patients and after first virological failure in a large community antiretroviral ther-
apy programme. Antivir Ther. 2009; 14: 523–31. Available: http://www.ncbi.nlm.nih.gov/pubmed/
19578237 PMID: 19578237
22. Yang W-L, Kouyos RD, Bo¨ni J, Yerly S, Klimkait T, Aubert V, et al. Persistence of Transmitted HIV-1
Drug Resistance Mutations Associated with Fitness Costs and Viral Genetic Backgrounds. Swanstrom
Modelling the spread of antiretroviral resistance in South Africa
PLOS Computational Biology | https://doi.org/10.1371/journal.pcbi.1007083 June 24, 2019 16 / 17
R, editor. PLOS Pathog. Public Library of Science; 2015; 11: e1004722. https://doi.org/10.1371/journal.
ppat.1004722 PMID: 25798934
23. Wittkop L, Gu¨nthard HF, de Wolf F, Dunn D, Cozzi-Lepri A, de Luca A, et al. Effect of transmitted drug
resistance on virological and immunological response to initial combination antiretroviral therapy for HIV
(EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect Dis. 2011; 11: 363–371.
https://doi.org/10.1016/S1473-3099(11)70032-9 PMID: 21354861
24. Patel P, Borkowf CB, Brooks JT, Lasry A, Lansky A, Mermin J. Estimating per-act HIV transmission
risk. AIDS. 2014; 28: 1509–1519. https://doi.org/10.1097/QAD.0000000000000298 PMID: 24809629
25. Anova Health Institute. Rapid Assessment of HIV Prevention, Care and Treatment Programming for
MSM in South Africa. 2013.
26. Brennan AT, Maskew M, Sanne I, Fox MP. The interplay between CD4 cell count, viral load suppression
and duration of antiretroviral therapy on mortality in a resource-limited setting. Trop Med Int Health. NIH
Public Access; 2013; 18: 619–31. https://doi.org/10.1111/tmi.12079 PMID: 23419157
27. Steegen K, Bronze M, Papathanasopoulos MA, van Zyl G, Goedhals D, Variava E, et al. HIV-1 antire-
troviral drug resistance patterns in patients failing NNRTI-based treatment: results from a national sur-
vey in South Africa. J Antimicrob Chemother. 2017; 72: 210–219. https://doi.org/10.1093/jac/dkw358
PMID: 27659733
28. Gupta RK, Gregson J, Parkin N, Haile-Selassie H, Tanuri A, Andrade Forero L, et al. HIV-1 drug resis-
tance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income
countries: a systematic review and meta-regression analysis. Lancet Infect Dis. Elsevier; 2018; 18:
346–355. https://doi.org/10.1016/S1473-3099(17)30702-8 PMID: 29198909
29. Mckay MD, Beckman RJ, Conover WJ. A Comparison of Three Methods for Selecting Values of Input
Variables in the Analysis of Output from a Computer Code. Technometrics. 1979; 21: 239–245. Avail-
able: https://www.jstor.org/stable/pdf/1268522.pdf?refreqid=excelsior%
3A5f8fe8a98ef89613eed62ad05ae4dd7c
30. Rosenberg MS, Go´mez-Olive´ FX, Rohr JK, Houle BC, Kabudula CW, Wagner RG, et al. Sexual Behav-
iors and HIV Status: A Population-Based Study Among Older Adults in Rural South Africa. J Acquir
Immune Defic Syndr. Wolters Kluwer Health; 2017; 74: e9–e17. https://doi.org/10.1097/QAI.
0000000000001173 PMID: 27926667
31. Parboosing R, Naidoo A, Gordon M, Taylor M, Vella V. Resistance to antiretroviral drugs in newly diag-
nosed, young treatment-naïve HIV-positive pregnant women in the province of KwaZulu-Natal, South
Africa. J Med Virol. 2011; 83: 1508–1513. https://doi.org/10.1002/jmv.22143 PMID: 21739439
32. Manasa J, Danaviah S, Lessells R, Elshareef M, Tanser F, Wilkinson E, et al. Increasing HIV-1 Drug
Resistance Between 2010 and 2012 in Adults Participating in Population-Based HIV Surveillance in
Rural KwaZulu-Natal, South Africa. AIDS Res Hum Retroviruses. Mary Ann Liebert, Inc.; 2016; 32:
763–9. https://doi.org/10.1089/AID.2015.0225 PMID: 27002368
33. Steegen K, Carmona S, Bronze M, Papathanasopoulos MA, van Zyl G, Goedhals D, et al. Moderate
Levels of Pre-Treatment HIV-1 Antiretroviral Drug Resistance Detected in the First South African
National Survey. Blackard J, editor. PLoS One. 2016; 11: e0166305. https://doi.org/10.1371/journal.
pone.0166305 PMID: 27907009
34. Yanik EL, Napravnik S, Hurt CB, Dennis A, Quinlivan EB, Sebastian J, et al. Prevalence of transmitted
antiretroviral drug resistance differs between acutely and chronically HIV-infected patients. J Acquir
Immune Defic Syndr. NIH Public Access; 2012; 61: 258–62. https://doi.org/10.1097/QAI.
0b013e3182618f05 PMID: 22692092
35. Hamers RL, Wallis CL, Kityo C, Siwale M, Mandaliya K. HIV-1 drug resistance in antiretroviral-naive
individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational
study. Artic Lancet Infect Dis. 2011; 11: 750–59. https://doi.org/10.1016/S1473
36. National Department of Health SA. FOR THE PREVENTION OF MOTHER-TO-CHILD TRANSMIS-
SION OF HIV (PMTCT) AND THE MANAGEMENT OF HIV IN CHILDREN, ADOLESCENTS AND
ADULTS NATIONAL CONSOLIDATED GUIDELINES [Internet]. 2014. Available: www.doh.gov.za
37. World Health Organization (WHO). WHO’s Response [Internet]. 2018. Available: http://www.who.int/
medicines/publications/drugalerts/Statement_on_DTG_18May_2018final.pdf
38. Wijting I, Rokx C, Boucher C, van Kampen J, Pas S, de Vries-Sluijs T, et al. Dolutegravir as mainte-
nance monotherapy for HIV (DOMONO): a phase 2, randomised non-inferiority trial. Lancet HIV. 2017;
4: e547–e554. https://doi.org/10.1016/S2352-3018(17)30152-2 PMID: 29107562
39. Blanco JL, Rojas J, Paredes R, Negredo E, Mallolas J, Casadella M, et al. Dolutegravir-based mainte-
nance monotherapy versus dual therapy with lamivudine: a planned 24 week analysis of the DOLAM
randomized clinical trial. J Antimicrob Chemother. 2018; 73: 1965–1971. https://doi.org/10.1093/jac/
dky093 PMID: 29608685
Modelling the spread of antiretroviral resistance in South Africa
PLOS Computational Biology | https://doi.org/10.1371/journal.pcbi.1007083 June 24, 2019 17 / 17
